Massachusetts-based diagnostics products manufacturer Inverness completed the acquisition through the merger of a wholly-owned subsidiary with and into Cholestech, after Cholestech's shareholders approved the deal.
Ron Zwanziger, chairman, president and CEO of Inverness, said: “The acquisition of Cholestech together with our recent and pending acquisitions, provides Inverness with the unique ability to assess cardiac risk, diagnose cardiac conditions and potentially monitor the condition and response to therapy of cardiac patients.”